Katharine Nicholson

ALS clinician researcher at Massachusetts General Hospital with specific interests in markers of disease in early familial ALS and the gut microbiome in ALS

[Katharine Nicholson @KNicholsonMD]

Exciting to provide clinical and research updates to our patients- from Amylyx and Tofersen to Prevent ALS! https://t.co/t7clQCTD9f

[Jean C9orf72 @Jeanc9orf72]

Stole this from an excellent talk by ⁦@KNicholsonMD⁩ - who can tell me how to have a diet that supplements the things in blue, and suppresses the things in orange?

[Katharine Nicholson @KNicholsonMD]

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS | Biogen https://t.co/eNuFy8MCF8

[NEALS Consortium @NEALSConsortium]

Join Dr. Richard Bedlack @dukealsclinic and Dr. Merit Cudkowicz @MGHNeurology for Part 6 of the #ALS Drug Development Webinar Series on September 15th https://t.co/fSuOEQ1YGY

[MLB @MLB]

30 signed Lou Gehrig Day baseballs across MLB + a one-of-a kind experience. All net proceeds will benefit the Expanded Access Protocol Program (EAP) at the Sean M. Healey & AMG Center for ALS.

The #LouGehrigDay Auction is live now: https://t.co/ey3AXpCunw

[Becky Mourey @becky_mourey]

A big heartfelt thank you to @RepAuchincloss for taking time out of his busy schedule today to meet with me and my family. I truly believe he will do everything in his power to help the ALS community. As I said today WE NEED YOU! Thank you! ❤️

[Sandy Morris @sandymorris333]

I can't emphasize this enough-the ALS Principles are the boundaries that people living with ALS have needed. 'What we allow will continue' and we must make sure we are building clear paths towards treatments for a horrendous disease, always working together so we get there faster

[NEALS Consortium @NEALSConsortium]

Join us this Friday at 3:30 PM ET for Part 4 of the #ALS Drug Development Webinar Series: Site Considerations https://t.co/QeU8mZQ6Pk

[Sabrina Paganoni, MD, PhD @PaganoniMDPhD]

#ALS #MND @MGHNeurology @alsassociation @iamalsorg @MDAorg @MDA_Advocacy @alsone_official

[Amylyx @AmylyxPharma]

We’re excited to announce our intention to submit a Marketing Authorization Application (MAA) for AMX0035 for the treatment of #ALS to the European Medicines Agency & the start of a Phase 3 trial in Europe & the U.S. https://t.co/9pIpySzbE4

[Amylyx @AmylyxPharma]

Today, we are excited to share news of our plans to submit a New Drug Submission for AMX0035 for the treatment of #ALS with Health Canada in the first half of 2021. This decision is based on the positive clinical data from the CENTAUR trial, and feedback from Health Canada.

[Coya Therapeutics @CoyaTx]

Coya Therapeutics announces merger with Nicoya Health and close of a $10 million Series A financing. Proceeds will be used to advance Coya's lead therapeutic program, ALS001: an off-the-shelf, autologous, expanded Treg cell therapy for ALS. #ALS https://t.co/eOGke4qg0f

[Sabrina Paganoni, MD, PhD @PaganoniMDPhD]

2020 was a turning point for #ALS research- thank you to our supporters and people who inspire our research ⁦@iamalsorg⁩ ⁦@sandymorris333⁩ ⁦@alsassociation⁩ ⁦@MDAorg⁩ ⁦@MGHNeurology⁩ https://t.co/7UweQNjE91

[Evan Campa @EvanCampa]

If the ALSFRS-R is the gold standard, it is a chocolate coin in gold foil masquerading as such and someday will be devoured by more objective measures

- a patient with a flair for the dramatic

#alsmndsymp @MGHNeurology @KNicholsonMD

[MGH Neurology @MGHNeurology]

In addition, a team from Mass General including @sheenachew, @PaganoniMDPhD, @LidiaMouraNVL and @KNicholsonMD has a poster on patient-reported outcomes and the ALSFRS-R and ABC scales.

Download clinical trial poster abstracts here: https://t.co/kTIzKLaur7

[Katharine Nicholson @KNicholsonMD]

@cherise77 Per the discussion session for this presentation live right now, additional data analysis needs to be done by @BrainstormCell to fully know next steps forward. This is a only a first look at the data- stay tuned!

[Katharine Nicholson @KNicholsonMD]

Incredible to finally see the results presented for the @BrainstormCell Therapeutics Phase 3 trial. A sincere thank you to all of the patients and caregivers involved in the trial, including those who partnered with @MGHNeurology for the trial! #alsmndsymp #HealeyHope

[Katharine Nicholson @KNicholsonMD]

Exciting new data presented by @PaganoniMDPhD from @AmylyxPharma and @ENCALS collaboration to predict a broader ALS population may have an up to 11.5 mo survival benefit from AMX0035! @MGHNeurology #alsmndsymp #HealeyHope

[MGH Neurology @MGHNeurology]

Today at the Intl. Symposium on ALS/MND check out the latest findings from @GSVLab together with @tpetrozziello assessing how DRP1 and tau affect mitochondrial fragmentation in ALS.
More info: https://t.co/D22xqv3igG
#HealeyHope #ALSSymp

[Katharine Nicholson @KNicholsonMD]

Thank you @PaganoniMDPhD @AmylyxPharma for presenting positive Centaur phase 2 results at #alsmndsymp with BOTH significant survival and functional benefits seen. Very exciting results for a well designed trial! Thank you to patients and caregivers from the study! @MGHNeurology

[Katharine Nicholson @KNicholsonMD]

A consistent robust treatment effect on CSF biomarkers of neuroinflammation/neuronal injury (reduced) and neuroprotection (increased) was seen in the Phase 3 @BrainstormCell trial. Important learnings for the entire ALS field! @MGHNeurology #alsmndsymp #HealeyHope